Skip to Content

Genmab A/S GNMSF

Morningstar Rating
$287.90 +0.30 (0.10%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GNMSF is trading at a 13% discount.
Price
$288.37
Fair Value
$249.98
Uncertainty
High
1-Star Price
$242.24
5-Star Price
$237.39
Economic Moat
Ksm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNMSF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$287.60
Day Range
$287.50294.20
52-Week Range
$262.00432.30
Bid/Ask
$260.09 / $320.66
Market Cap
$18.80 Bil
Volume/Avg
377 / 1,086

Key Statistics

Price/Earnings (Normalized)
20.45
Price/Sales
7.51
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.43%

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
2,204

Competitors

Valuation

Metric
GNMSF
4502
INCY
Price/Earnings (Normalized)
20.4514.4716.43
Price/Book Value
3.791.012.50
Price/Sales
7.511.653.54
Price/Cash Flow
20.578.5717.55
Price/Earnings
GNMSF
4502
INCY

Financial Strength

Metric
GNMSF
4502
INCY
Quick Ratio
13.320.463.55
Current Ratio
13.341.063.75
Interest Coverage
175.001.93260.45
Quick Ratio
GNMSF
4502
INCY

Profitability

Metric
GNMSF
4502
INCY
Return on Assets (Normalized)
16.09%2.86%12.82%
Return on Equity (Normalized)
17.97%6.13%16.79%
Return on Invested Capital (Normalized)
15.16%4.78%14.10%
Return on Assets
GNMSF
4502
INCY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYcqg$550.2 Bil
VRTX
Vertex Pharmaceuticals IncZmchq$111.1 Bil
REGN
Regeneron Pharmaceuticals IncQqzvs$107.7 Bil
MRNA
Moderna IncLbm$36.9 Bil
ARGX
argenx SE ADRYkc$24.2 Bil
BNTX
BioNTech SE ADRVdbdk$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncCvwnzy$19.9 Bil
BMRN
Biomarin Pharmaceutical IncGdshwcx$17.2 Bil
RPRX
Royalty Pharma PLC Class AJjdwjq$13.9 Bil
INCY
Incyte CorpSztqkj$13.6 Bil

Sponsor Center